Working… Menu

Effects of Vitamin D on Inflammation in Liver Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01754961
Recruitment Status : Unknown
Verified December 2012 by Mario Chojkier, Veterans Medical Research Foundation.
Recruitment status was:  Recruiting
First Posted : December 21, 2012
Last Update Posted : December 21, 2012
Information provided by (Responsible Party):
Mario Chojkier, Veterans Medical Research Foundation

Brief Summary:
Chronic liver diseases are associated with inflammation. The investigators postulate that Vitamin D may modulate inflammation. Thus the investigators will study the effect of Vitamin D replacement in patients with Hepatitis C infection and Vitamin D deficiency.

Condition or disease Intervention/treatment Phase
Hepatitis C Infection Vitamin D Deficiency Drug: Vitamin D Drug: Placebo Phase 2

Detailed Description:

Vitamin D appears to be a critical signaling molecule for macrophages because is needed for activation and differentiation of monocytes/macrophages. From our Preliminary Studies( VA Merit Review Grant), we propose that Vitamin D deficiency may alter the 'pro-inflammatory' ('classically activated') M1 macrophages , characterized by i] high expression of NOS2, TNF-a, IL-1, IL-6, IL-8, TGF-a, CXCL10, and CCL19; and ii] minimal expression of arginase 1 and mannose R.

The clinical relevance of these findings is suggested by the presence of activated M1 macrophages in liver biopsies from patients with severe drug-induced liver injury (unpublished observations).

Prospective vitamin D supplementation studies with appropriate endpoints are needed to define the role of vitamin D on inflammation in patients with chronic liver diseases.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Effects of Vitamin D on Inflammation in Liver Disease
Study Start Date : November 2011
Estimated Primary Completion Date : October 2013
Estimated Study Completion Date : January 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Vitamin D

Arm Intervention/treatment
Placebo Comparator: Placebo
Placebo will be given on Day 1 orally
Drug: Placebo
Placebo given orally on Day 1
Other Name: Emulsion placebo

Active Comparator: Vitamin D
Administration of 500,000 IU Vitamin D orally on Day 1
Drug: Vitamin D
Vitamin D 500,000 IU given orally on Day 1
Other Name: Vitamin D Drug

Primary Outcome Measures :
  1. Macrophage activation [ Time Frame: one week ]
    As determined by serum levels and macrophage cytokine production compared to placebo and baseline

Secondary Outcome Measures :
  1. Liver injury [ Time Frame: one week ]
    Measurement of ALT/AST

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men or women aged 18 or older
  • Total 25-OH Vit D < 25 ng/mL
  • Infection with HCV genotype 1 (subjects infected with multiple genotypes are not eligible).
  • Plasma HCV RNA concentration of >100,000 IU/mL.
  • HCV-infected subjects naïve to treatment: subjects who either have never been treated for HCV infection or who previously received HCV treatment ending > 3 months prior to enrollment (including, any IFN-Alpha with or without ribavirin, or other anti-HCV antiviral medication).

Exclusion Criteria:

  • Women who are pregnant or breastfeeding.
  • Patients with Sarcoidosis, Histoplasmosis, Lymphoma, Primary Hyperparathyroidism or Idiophatic Hypercalcemia.
  • Liver Cirrhosis.
  • Known active gastrointestinal disease that could interfere with the absorption of the test article.
  • Laboratory determinations at screening as follows:
  • Hemoglobin <10 g/dL .
  • Serum creatinine that is not within normal limits. However, such subjects may be enrolled if the Cockroft-Gault glomerular filtration rate (GFR) is > 50 mL/minute.
  • Unstable hypertension, cardiac disease or type 2 diabetes requiring changes in treatment with medications 4 weeks prior to screening or during the screening period.
  • Use of an investigational drug within 4 weeks before the screening visit or during the screening period.
  • Use of systemic immunosuppressants (including systemic, oral, or intravenous corticosteroids) or immunomodulating agents within 4 weeks before the screening visit or during the screening period.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01754961

Layout table for location contacts
Contact: Kim Inocencio, BS 619-717-1906

Layout table for location information
United States, California
UC San Diego, CTRI Recruiting
La Jolla, California, United States, 92093
Contact: Kim Inocencio, BS    619-717-1906   
Principal Investigator: Mario Chojkier, MD         
Sponsors and Collaborators
Veterans Medical Research Foundation
Layout table for investigator information
Principal Investigator: Mario Chojkier, MD University of California, San Diego
Layout table for additonal information
Responsible Party: Mario Chojkier, Professor of Medicine, Veterans Medical Research Foundation Identifier: NCT01754961    
Other Study ID Numbers: UCSD-111219
First Posted: December 21, 2012    Key Record Dates
Last Update Posted: December 21, 2012
Last Verified: December 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis C
Liver Diseases
Vitamin D Deficiency
Digestive System Diseases
Pathologic Processes
Hepatitis, Viral, Human
Virus Diseases
Flaviviridae Infections
RNA Virus Infections
Deficiency Diseases
Nutrition Disorders
Vitamin D
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents
Calcium-Regulating Hormones and Agents